ARISTADA
- Product NDC
- 65757-402
- Requested package NDC
- 65757-402-03
- 11-digit product format
- 657570402
- Labeler code
- 65757
- Product ID
- 65757-402_3d951a36-1e73-4f84-8ebf-4d556d81a086
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- aripiprazole lauroxil
- Dosage form
- INJECTION, SUSPENSION, EXTENDED RELEASE
- Route
- INTRAMUSCULAR
- Labeler
- Alkermes, Inc.
- Application
- NDA207533
- Marketing category
- NDA
- Marketing start
- 2015-10-05
- Substance
- ARIPIPRAZOLE LAUROXIL
- Active strength
- 662 mg/2.4mL
- Pharmacologic classes
- Atypical Antipsychotic [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N207533-001 | ARISTADA | ARIPIPRAZOLE LAUROXIL | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | |
| N207533-002 | ARISTADA | ARIPIPRAZOLE LAUROXIL | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | |
| N207533-003 | ARISTADA | ARIPIPRAZOLE LAUROXIL | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | |
| N207533-004 | ARISTADA | ARIPIPRAZOLE LAUROXIL | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N207533-001 | 10112903 | 2030-06-24 | U-543 | Drug substance | 2018-11-20 |
| N207533-001 | 8796276 | 2030-06-24 | U-543 | 2015-10-14 | |
| N207533-001 | 8431576 | 2030-10-26 | Drug substance | 2015-10-14 | |
| N207533-001 | 10226458 | 2032-03-19 | U-543 | 2019-04-08 | |
| N207533-001 | 9034867 | 2032-11-07 | U-543 | Drug product | 2015-10-14 |
| N207533-001 | 12629366 | 2032-12-06 | U-764 | Drug product | 2026-06-18 |
| N207533-001 | 11097006 | 2033-09-19 | U-764 | Drug product | 2021-10-21 |
| N207533-001 | 12311027 | 2033-09-19 | U-543 | Drug product | 2025-07-17 |
| N207533-001 | 9193685 | 2033-10-24 | U-543 | Drug product | 2015-12-09 |
| N207533-001 | 11969469 | 2034-04-06 | Drug product | 2024-05-16 | |
| N207533-001 | 10238651 | 2035-03-19 | U-2402 | 2019-04-08 | |
| N207533-001 | 10813928 | 2035-03-19 | U-2983 | 2020-11-10 | |
| N207533-001 | 11406632 | 2035-03-19 | U-2402 | 2022-08-19 | |
| N207533-001 | 12653822 | 2035-03-19 | U-2402 | 2026-07-15 | |
| N207533-001 | 9452131 | 2035-03-19 | U-2402 | 2016-10-05 | |
| N207533-001 | 11273158 | 2039-04-06 | U-543 | 2022-04-13 | |
| N207533-001 | 12251381 | 2039-04-06 | U-543 | 2025-04-08 | |
| N207533-002 | 10112903 | 2030-06-24 | U-543 | Drug substance | 2018-11-20 |
| N207533-002 | 8796276 | 2030-06-24 | U-543 | 2015-10-14 | |
| N207533-002 | 8431576 | 2030-10-26 | Drug substance | 2015-10-14 | |
| N207533-002 | 10226458 | 2032-03-19 | U-543 | 2019-04-08 | |
| N207533-002 | 9034867 | 2032-11-07 | U-543 | Drug product | 2015-10-14 |
| N207533-002 | 12629366 | 2032-12-06 | U-764 | Drug product | 2026-06-18 |
| N207533-002 | 11097006 | 2033-09-19 | U-764 | Drug product | 2021-10-21 |
| N207533-002 | 12311027 | 2033-09-19 | U-543 | Drug product | 2025-07-17 |
| N207533-002 | 9193685 | 2033-10-24 | U-543 | Drug product | 2015-12-09 |
| N207533-002 | 11969469 | 2034-04-06 | Drug product | 2024-05-16 | |
| N207533-002 | 10238651 | 2035-03-19 | U-2402 | 2019-04-08 | |
| N207533-002 | 10813928 | 2035-03-19 | U-2983 | 2020-11-10 | |
| N207533-002 | 11406632 | 2035-03-19 | U-2402 | 2022-08-19 | |
| N207533-002 | 12653822 | 2035-03-19 | U-2402 | 2026-07-15 | |
| N207533-002 | 9452131 | 2035-03-19 | U-2402 | 2016-10-05 | |
| N207533-002 | 9526726 | 2035-03-19 | Drug product | 2017-01-19 | |
| N207533-002 | 11273158 | 2039-04-06 | U-543 | 2022-04-13 | |
| N207533-002 | 12251381 | 2039-04-06 | U-543 | 2025-04-08 | |
| N207533-003 | 10112903 | 2030-06-24 | U-543 | Drug substance | 2018-11-20 |
| N207533-003 | 8796276 | 2030-06-24 | U-543 | 2015-10-14 | |
| N207533-003 | 8431576 | 2030-10-26 | Drug substance | 2015-10-14 | |
| N207533-003 | 10226458 | 2032-03-19 | U-543 | 2019-04-08 | |
| N207533-003 | 9034867 | 2032-11-07 | U-543 | Drug product | 2015-10-14 |
| N207533-003 | 12629366 | 2032-12-06 | U-764 | Drug product | 2026-06-18 |
| N207533-003 | 11097006 | 2033-09-19 | U-764 | Drug product | 2021-10-21 |
| N207533-003 | 12311027 | 2033-09-19 | U-543 | Drug product | 2025-07-17 |
| N207533-003 | 9193685 | 2033-10-24 | U-543 | Drug product | 2015-12-09 |
| N207533-003 | 11969469 | 2034-04-06 | Drug product | 2024-05-16 | |
| N207533-003 | 10238651 | 2035-03-19 | U-2402 | 2019-04-08 | |
| N207533-003 | 10813928 | 2035-03-19 | U-2402 | 2020-11-10 | |
| N207533-003 | 11406632 | 2035-03-19 | U-2402 | 2022-08-19 | |
| N207533-003 | 12653822 | 2035-03-19 | U-2402 | 2026-07-15 | |
| N207533-003 | 9452131 | 2035-03-19 | U-2402 | 2016-10-05 | |
| N207533-003 | 9526726 | 2035-03-19 | Drug product | 2017-01-19 | |
| N207533-003 | 11273158 | 2039-04-06 | U-543 | 2022-04-13 | |
| N207533-003 | 12251381 | 2039-04-06 | U-543 | 2025-04-08 | |
| N207533-004 | 10112903 | 2030-06-24 | U-543 | Drug substance | 2018-11-20 |
| N207533-004 | 8796276 | 2030-06-24 | U-543 | 2017-06-27 | |
| N207533-004 | 8431576 | 2030-10-26 | Drug substance | 2017-06-27 | |
| N207533-004 | 10226458 | 2032-03-19 | U-543 | 2019-04-08 | |
| N207533-004 | 9034867 | 2032-11-07 | U-543 | Drug product | 2017-06-27 |
| N207533-004 | 12629366 | 2032-12-06 | U-764 | Drug product | 2026-06-18 |
| N207533-004 | 11097006 | 2033-09-19 | U-764 | Drug product | 2021-10-21 |
| N207533-004 | 12311027 | 2033-09-19 | U-543 | Drug product | 2025-07-17 |
| N207533-004 | 9193685 | 2033-10-24 | U-543 | Drug product | 2017-06-27 |
| N207533-004 | 11969469 | 2034-04-06 | Drug product | 2024-05-16 | |
| N207533-004 | 10238651 | 2035-03-19 | U-2402 | 2019-04-08 | |
| N207533-004 | 10813928 | 2035-03-19 | U-2983 | 2020-11-10 | |
| N207533-004 | 11406632 | 2035-03-19 | U-2402 | 2022-08-19 | |
| N207533-004 | 12653822 | 2035-03-19 | U-2402 | 2026-07-15 | |
| N207533-004 | 9452131 | 2035-03-19 | U-2402 | 2017-06-27 | |
| N207533-004 | 11273158 | 2039-04-06 | U-543 | 2022-04-13 | |
| N207533-004 | 12251381 | 2039-04-06 | U-543 | 2025-04-08 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N207533-001 | ARISTADA | 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N207533-002 | ARISTADA | 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2015-10-05 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N207533-003 | ARISTADA | 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD, RS | 2015-10-05 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N207533-004 | ARISTADA | 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | RLD | 2017-06-05 | 5bbf6a4d5a75… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 10112903 | 2030-06-24 | U-543 | Drug substance | 2018-11-20 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 8796276 | 2030-06-24 | U-543 | 2015-10-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 8431576 | 2030-10-26 | Drug substance | 2015-10-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 10226458 | 2032-03-19 | U-543 | 2019-04-08 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 9034867 | 2032-11-07 | U-543 | Drug product | 2015-10-14 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 12629366 | 2032-12-06 | U-764 | Drug product | 2026-06-18 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 11097006 | 2033-09-19 | U-764 | Drug product | 2021-10-21 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 12311027 | 2033-09-19 | U-543 | Drug product | 2025-07-17 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 9193685 | 2033-10-24 | U-543 | Drug product | 2015-12-09 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 11969469 | 2034-04-06 | Drug product | 2024-05-16 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 10238651 | 2035-03-19 | U-2402 | 2019-04-08 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 10813928 | 2035-03-19 | U-2983 | 2020-11-10 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 11406632 | 2035-03-19 | U-2402 | 2022-08-19 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 12653822 | 2035-03-19 | U-2402 | 2026-07-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 9452131 | 2035-03-19 | U-2402 | 2016-10-05 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 11273158 | 2039-04-06 | U-543 | 2022-04-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-001 | 12251381 | 2039-04-06 | U-543 | 2025-04-08 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 10112903 | 2030-06-24 | U-543 | Drug substance | 2018-11-20 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 8796276 | 2030-06-24 | U-543 | 2015-10-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 8431576 | 2030-10-26 | Drug substance | 2015-10-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 10226458 | 2032-03-19 | U-543 | 2019-04-08 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 9034867 | 2032-11-07 | U-543 | Drug product | 2015-10-14 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 12629366 | 2032-12-06 | U-764 | Drug product | 2026-06-18 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 11097006 | 2033-09-19 | U-764 | Drug product | 2021-10-21 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 12311027 | 2033-09-19 | U-543 | Drug product | 2025-07-17 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 9193685 | 2033-10-24 | U-543 | Drug product | 2015-12-09 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 11969469 | 2034-04-06 | Drug product | 2024-05-16 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 10238651 | 2035-03-19 | U-2402 | 2019-04-08 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 10813928 | 2035-03-19 | U-2983 | 2020-11-10 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 11406632 | 2035-03-19 | U-2402 | 2022-08-19 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 12653822 | 2035-03-19 | U-2402 | 2026-07-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 9452131 | 2035-03-19 | U-2402 | 2016-10-05 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 9526726 | 2035-03-19 | Drug product | 2017-01-19 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 11273158 | 2039-04-06 | U-543 | 2022-04-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-002 | 12251381 | 2039-04-06 | U-543 | 2025-04-08 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-003 | 10112903 | 2030-06-24 | U-543 | Drug substance | 2018-11-20 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N207533-003 | 8796276 | 2030-06-24 | U-543 | 2015-10-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-003 | 8431576 | 2030-10-26 | Drug substance | 2015-10-14 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-003 | 10226458 | 2032-03-19 | U-543 | 2019-04-08 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N207533-003 | 9034867 | 2032-11-07 | U-543 | Drug product | 2015-10-14 | 84e616aacf4f… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N207533-001 | NCE | 2020-10-05 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N207533-002 | NCE | 2020-10-05 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N207533-003 | NCE | 2020-10-05 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N207533-004 | NCE | 2020-10-05 | 74a2ff9319b5… |
| 2020-12-22 03:56 UTC | 2020-12 | N207533-001 | NCE | 2020-10-05 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | N207533-002 | NCE | 2020-10-05 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | N207533-003 | NCE | 2020-10-05 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | N207533-004 | NCE | 2020-10-05 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N207533-001 | NCE | 2020-10-05 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | N207533-002 | NCE | 2020-10-05 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | N207533-003 | NCE | 2020-10-05 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | N207533-004 | NCE | 2020-10-05 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N207533-001 | NCE | 2020-10-05 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N207533-002 | NCE | 2020-10-05 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N207533-003 | NCE | 2020-10-05 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N207533-004 | NCE | 2020-10-05 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N207533-001 | NCE | 2020-10-05 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N207533-002 | NCE | 2020-10-05 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N207533-003 | NCE | 2020-10-05 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N207533-004 | NCE | 2020-10-05 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N207533-001 | NCE | 2020-10-05 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N207533-002 | NCE | 2020-10-05 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N207533-003 | NCE | 2020-10-05 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N207533-004 | NCE | 2020-10-05 | ea99ee380514… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- ARISTADA
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| ARIPIPRAZOLE LAUROXIL | 662 mg/2.4mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| B786J7A343 | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 1673269 | Internal RxNorm lookup |
| 1673274 | Internal RxNorm lookup |
| 1673277 | Internal RxNorm lookup |
| 1673278 | Internal RxNorm lookup |
| 1673279 | Internal RxNorm lookup |
| 1673280 | Internal RxNorm lookup |
| 1925262 | Internal RxNorm lookup |
| 1925264 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | Available on FDA.report |
DailyMed Product Concepts#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 65757-402-03 | ARISTADA | 1 in 1 CARTON | INJECTION, SUSPENSION, EXTENDED | 1 | 32 | |
| 65757-402-03 | ARISTADA | 2.4 mL in 1 SYRINGE | INJECTION, SUSPENSION, EXTENDED | 2.4 | 32 | |
| 65757-402-04 | ARISTADA | 1 in 1 CARTON | INJECTION, SUSPENSION, EXTENDED | 1 | 32 | |
| 65757-402-04 | ARISTADA | 2.4 mL in 1 SYRINGE | INJECTION, SUSPENSION, EXTENDED | 2.4 | 32 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 65757-402-01 | ML - Milliliter | 65757-402 | 0bf05b99-9ee0-4776-8976-9becf64eabb0 | 1 | 2015-12-02 |
| 65757-402-03 | ML - Milliliter | 65757-402 | 1be5b7e2-e85b-4054-8257-a932387085be | 1 | 2015-11-12 |
DailyMed Socrata Ingredients#
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ARISTADA | ARIPIPRAZOLE LAUROXIL | Alkermes, Inc. | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 2025-01-28 | Boxed warning, Warnings, Adverse reactions | 207533 NDA207533 65757-402-03 65757-402 65757040203 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 1925262 | ARIPiprazole lauroxil 1064 MG in 3.9 ML Prefilled Syringe | PSN | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673269 | ARIPiprazole lauroxil 441 MG in 1.6 ML Prefilled Syringe | PSN | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673277 | ARIPiprazole lauroxil 662 MG in 2.4 ML Prefilled Syringe | PSN | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673279 | ARIPiprazole lauroxil 882 MG in 3.2 ML Prefilled Syringe | PSN | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1925264 | Aristada 1064 MG in 3.9 ML Prefilled Syringe | PSN | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673274 | Aristada 441 MG in 1.6 ML Prefilled Syringe | PSN | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673278 | Aristada 662 MG in 2.4 ML Prefilled Syringe | PSN | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673280 | Aristada 882 MG in 3.2 ML Prefilled Syringe | PSN | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673274 | 1.6 ML aripiprazole lauroxil 276 MG/ML Prefilled Syringe [Aristada] | SBD | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673278 | 2.4 ML aripiprazole lauroxil 276 MG/ML Prefilled Syringe [Aristada] | SBD | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673280 | 3.2 ML aripiprazole lauroxil 276 MG/ML Prefilled Syringe [Aristada] | SBD | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1925264 | 3.9 ML aripiprazole lauroxil 273 MG/ML Prefilled Syringe [Aristada] | SBD | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673269 | 1.6 ML aripiprazole lauroxil 276 MG/ML Prefilled Syringe | SCD | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673277 | 2.4 ML aripiprazole lauroxil 276 MG/ML Prefilled Syringe | SCD | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673279 | 3.2 ML aripiprazole lauroxil 276 MG/ML Prefilled Syringe | SCD | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1925262 | 3.9 ML aripiprazole lauroxil 273 MG/ML Prefilled Syringe | SCD | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1925264 | 3.9 ML Aristada 273 MG/ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1925262 | aripiprazole lauroxil 1064 MG per 3.9 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673277 | aripiprazole lauroxil 276 MG/ML per 2.4 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673279 | aripiprazole lauroxil 276 MG/ML per 3.2 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673269 | aripiprazole lauroxil 441 MG per 1.6 ML Extended Release Suspension Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673269 | aripiprazole lauroxil 441 MG per 1.6 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673277 | aripiprazole lauroxil 662 MG per 2.4 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673279 | aripiprazole lauroxil 882 MG per 3.2 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1925264 | Aristada 1064 MG per 3.9 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1925264 | Aristada 273 MG/ML per 3.9 ML Prefilled | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673278 | Aristada 276 MG/ML per 2.4 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673280 | Aristada 276 MG/ML per 3.2 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673274 | Aristada 441 MG per 1.6 ML Extended Release Suspension Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673274 | Aristada 441 MG per 1.6 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673278 | Aristada 662 MG per 2.4 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
| 1673280 | Aristada 882 MG per 3.2 ML Prefilled Syringe | SY | 17a8d11b-73b0-4833-a0b4-cf1ef85edefb | 32 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 65757-402-03 | 65757040203 | 1 SYRINGE in 1 CARTON (65757-402-03) / 2.4 mL in 1 SYRINGE | 1 syringe | 2015-10-05 | 0000-00-00 | No | No | Current |